This collaboration aims to revolutionize precision medicine and artificial intelligence (AI)-enabled digital pathology solutions for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH) clinical trials. Summary of the Article:Collaborative Effort: The collaboration between Alimentiv, AcelaBio, and PharmaNest focuses on enhancing clinical trial methodologies for MASH, a disease with no approved therapies and a growing impact. Integration of Technologies: The partnership aims to integrate high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis. This integrated approach is expected to enable high-quality end-to-end tissue assays, allowing clinical trial sponsors to drive scientific…
Author: Abhay Panchal
The article discusses ADR in colorectal cancer screening” discusses a study presented at the ACG Annual Scientific Meeting, which found that Endocuff-assisted colonoscopy (EAC) is more effective than standard colonoscopy in detecting polyps and estimating adenoma detection rates in colorectal cancer screening. Summary of the Article:Study Findings: The study, led by Seth A. Gross, MD, analyzed data from 893,560 screening colonoscopies performed between 2018 and 2021. It was found that the polyp detection rate (PDR) in the Endocuff-assisted group was 72% compared to 57.4% in the standard colonoscopy group. Similarly, the estimated adenoma detection rate (eADR) was higher in the…
The article titled “ACLF with recompensated cirrhosis has ‘generally milder’ severity, better prognosis” discusses a study on the severity and prognosis of acute-on-chronic liver failure (ACLF) in patients with recompensated cirrhosis compared to those with decompensated cirrhosis. Summary of the Article:Study Overview: Conducted by Haixia Yuan and colleagues, the study retrospectively evaluated 461 patients with ACLF at Tianjin Third Central Hospital between May 2009 and May 2019. The patients were categorized into three groups: ACLF with compensated cirrhosis, ACLF with decompensated cirrhosis, and ACLF with recompensated cirrhosis. Clinical Features and Severity: Patients with recompensated cirrhosis had higher levels of hemoglobin,…
The article discusses the challenges in the use of metoclopramide for patients with upper gastrointestinal bleeding due to the limited availability of published trial data. Summary of the Article:Metoclopramide for Upper GI Bleeding: Metoclopramide, a drug commonly used to enhance endoscopic visualization in patients with upper GI bleeding, lacks sufficient published trial data to support its widespread use. This contrasts with erythromycin, another prokinetic drug, which has a robust evidence base and guideline endorsement. Study Findings: A systematic review and meta-analysis conducted by Faisal S. Ali, MD, and colleagues found six abstracts from randomized controlled trials involving metoclopramide. These trials…
A novel multitarget stool RNA test for colorectal cancer screening achieved a sensitivity of 100% for CRC and 44% for advanced adenomas in patients aged 45 to 49, according to data from the CRC-PREVENT trial. This younger age bracket, which made up 24% of the full study population, are now included in CRC screening recommendations, but until now, have not been specifically studied. Noninvasive screening test efficacy data are lacking for this age group, according to senior investigator David S. Lieberman, MD, a professor of medicine and former chief of gastroenterology at Oregon Health & Science University, in Portland.
American Gastroenterological Association’s (AGA) stance on the management of patients taking glucagon-like peptide 1 (GLP-1) receptor agonists before endoscopy procedures. Summary of the Article:AGA’s Stance: The AGA has released a rapid clinical practice update in response to the American Society of Anesthesiologists’ recommendation for patients to stop taking GLP-1 receptor agonists (GLP-1 RAs) before elective procedures and surgeries. The AGA does not support the idea of all patients discontinuing these drugs prior to elective endoscopy. GLP-1 Receptor Agonists: These medications, including Ozempic® (semaglutide) and Trulicity® (dulaglutide), are commonly prescribed for diabetes and obesity treatment. They might slow gastric emptying in…
Dr. Benjamin H. Levy III, discusses the challenges faced by gastroenterologists due to insurance companies’ prior authorization requirements for procedures like screening and diagnostic colonoscopies. Summary of the Article: Prior Authorization Concerns: There has been a recent push by insurance companies to implement prior authorization for preventive medicine procedures, which could lead to delays in healthcare delivery and increased costs. This would necessitate additional administrative staff to handle the increased paperwork. Gastroenterologists’ Response: The gastroenterology community has been actively urging health insurance companies to collaborate with professional organizations like the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA),…
The study aimed to evaluate the auxiliary diagnostic performance of an AI system in detecting superficial oesophageal squamous cell carcinoma and precancerous lesions using white light endoscopy (WLE) and non-magnified narrow-band imaging (NBI). Conducted across 12 hospitals in China, the trial involved patients undergoing sedated upper gastrointestinal endoscopy for various reasons. Participants were randomly assigned to either an AI-first or a routine-first group, with the endoscopist performing examinations with and without AI assistance. Key findings include: Insights:
Dive deep with Dr. Michael Byrne, CEO & Founder of Satisfai Health, as he discusses the transformative potential of Artificial Intelligence (AI) in Gastroenterology (GI). This conversation is a treasure trove for anyone keen on understanding the future of AI in medicine and its implications for the healthcare industry. Highlights: Dr. Byrne believes, “The healthcare system in general will see the utility and the benefit of AI… the benefits of AI in medicine, in GI, in endoscopy are literally huge.” Don’t miss this one.
Major tech companies have been making significant strides in the healthcare sector, and their progress has been closely monitored and analyzed. Based on the 2023 scores on the Health, Innovation & Tech (HIT) Index, here’s a power ranking of the most influential non-healthcare players in the healthcare industry: